GlassScriptPhysician profile
Lauren Eschmann
NPI 1316475734
$2,727.61
in general payments reported to CMS, 2019-2025
19 companies · $734 in 2025
The $734 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $221 · 2022: $659 · 2023: $461 · 2024: $652 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,061.21 | 2021-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Novo Nordisk INC | $696.96 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $253.41 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $129.75 | 2022-2025 | |
| Astellas Pharma US INC | $94.99 | 2022 | |
| Lilly USA, LLC | $77.07 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.84 | 2022-2024 | Jardiance |
| Amgen INC. | $57.87 | 2023-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $51.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $32.81 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.13 | 2023 | Verquvo, Belsomra, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $27.98 | 2022 | |
| Ardelyx, INC. | $26.72 | 2025 | Ibsrela |
| Corcept Therapeutics | $20.52 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $20.49 | 2025 | Voquezna |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $19.66 | 2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.28 | 2024 | Xifaxan |
| Dexcom, INC. | $17.58 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.05 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Eschmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.